Tuesday, June 14, 2022 8:01:25 AM
Development Technologies Corp. (formerly Pegasus Pharmaceuticals Inc.) (the "Company") has completed a name change to Development Technologies Corp as well as a symbol change to DVTC. Additionally, a 1 for 1,000 stock split was effectuated in early May 2022.
On June 8th 2022, the Company executed a definitive agreement to purchase 25% of Castle Heights West LLC in exchange for 750,021 shares of common stock of the Company. The closing is scheduled to take place on or before June 20,2022. Samuel Eisenberg, the Companys CEO, is also the managing member of Castle Heights West, LLC. The terms of the agreement were completed at arms-length.
The Company launched a website to provide ongoing information of its new direction as a Real Estate Technology Company. www.developmenttechnologiescorp.com.
The new website is in beta form. However, it provides information of the new direction the Company has taken. Samuel Eisenberg, the current CEO, has announced the potential acquisition of certain real estate operations and assets.
Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM